

# Ultra-high Dose Radiation for Liver Metastasis Using MR-guided Treatment With Stereotactic Ablative Single-fraction

NCT06362395

---

Status	RECRUITING
Phase	Phase 3
Sponsor	University Health Network, Toronto
Enrollment	114 participants

## Key Eligibility Criteria

---

### Inclusion (13)

- Histologically confirmed malignancy (colorectal adenocarcinoma, pancreatic adenocarcinoma, head and neck SCC, cervix SCC, skin SCC and NSCLC) with metastatic liver disease detected on imaging. Biopsy of metastasis is preferred, but not mandatory.
- One, two or three liver metastases "target lesion", e 2 cm from luminal and biliary structures
- Target lesion(s) that can receive high/ultra-high dose SBRT: Maximum number: 3, Maximum diameter of each target lesion: 6cm
- Non-target lesion(s) can be treated with 3- or 5-fraction SBRT for non-target liver metastases
- Patients must be Child-Pugh score A within one month prior to study entry.

... and 8 more (see full listing online)

### Exclusion (14)

- Liver metastases from primary cancer other than listed in the eligibility criteria (i.e., tumor with low  $\pm$ ratio).
- Target lesion "planned for high/ultra-high dose SBRT" in proximity ( $\leq$ 2cm) to luminal or biliary structures.
- Evidence of  $\geq$  5 liver metastases (exception is in cases of oligoprogression, patients may have more than 5 liver metastases, but SBRT for target lesions will be required for 1, 2, or 3 liver metastases only).
- Any previous RT to the abdomino-pelvic region that would result in significant overlap of RT volume for the current study.
- Previous liver-directed transarterial radioembolization (note that previous transarterial chemoembolization, microwave ablation, or radiofrequency ablation are permitted).

... and 9 more (see full listing online)

## Locations (1 total)

---

Princess Margaret Cancer Centre, Toronto, Ontario, Canada